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OBJECTIVES: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS)
requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to
evaluate long-term safety and efficacy of teduglutide.
METHODS: Enrolled patients had completed 24 weeks of either teduglutide (TED/TED) or placebo (PBO/TED) in the initial placebo-
controlled study or qualified for that study, but were not treated (NT/TED) because of full enrollment. Patients received
subcutaneous teduglutide 0.05 mg/kg/day for up to 24 months (NT/TED and PBO/TED) or up to 30 months (TED/TED). Clinical
response was defined as 20–100% reduction from baseline in weekly PS volume; baseline was considered the beginning of
teduglutide treatment in the initial placebo-controlled study (TED/TED) or STEPS-2 (NT/TED and PBO/TED). Descriptive statistics
summarized changes in efficacy and safety variables.
RESULTS: Of 88 enrolled patients, 65 (74%) completed STEPS-2. The most common treatment-emergent adverse events were
abdominal pain (34%), catheter sepsis (28%), and decreased weight (25%). Mean weight, body mass index, and serum albumin
remained stable. In patients who completed the study, clinical response was achieved in 28/30 (93%) TED/TED, 16/29 (55%) PBO/
TED, and 4/6 (67%) NT/TED patients. Mean PS volume reductions from baseline were 7.6 (66%), 3.1 (28%), and 4.0 (39%) l/week in
the TED/TED, PBO/TED, and NT/TED groups, respectively. Thirteen patients achieved full enteral autonomy.
CONCLUSIONS: In patients with SBS, long-term teduglutide treatment resulted in sustained, continued reductions in PS
requirements. Overall health and nutritional status was maintained despite PS reductions.
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INTRODUCTION
Short bowel syndrome (SBS) is a malabsorptive condition
characterized by an extreme reduction in functional intestinal
length.1 In the past, SBS has been defined by the presence of
less than 150–200 cm of postduodenal small intestine.2,3
However, within this population, there is a spectrum of bowel
dysfunction ranging from compensated intestinal insufficiency
to intestinal failure (SBS-IF) requiring parenteral support (PS;
consisting of parenteral nutrition and/or intravenous fluids)
because the extent of bowel function depends on the health
and anatomy of the residual bowel and the degree of
compensatory intestinal and physiologic adaptation following
resection.1,4,5 Thus, more recently, SBS-IF has been
operationally defined as loss of absorptive capacity character-
ized by the inability to maintain proper hydration or protein-
energy, electrolyte, or micronutrient balances while conform-
ing to a conventional diet.6
SBS-IF is frequently associated with severe diarrhea, abdom-
inal pain, dehydration, and malnutrition.7 Despite changes in
PS constituents and improvements in catheter care in recent
years, PS-dependent patients remain at risk for potentially
life-threatening complications, including catheter-related central
line sepsis, loss of vascular access, and progressive liver
dysfunction.8–11 Among PS-dependent patients, catheter-related
bloodstream infections occur at a rate of between 0.38 and 4.58
episodes/1000 catheter days.12 In addition, PS dependence in
patients with SBS is associated with a reduced quality of life.10,13
Patients who require chronic PS report disruptions in lifestyle,
social engagement, and sleep patterns.10Primary disease-related
concerns for patientswithSBS-IF includeworries about burdening
others, low energy levels, isolation, and fear of surgery.13
Intestinal rehabilitation for patients with SBS is aimed at
controlling symptoms of malabsorption, optimizing nutritional
status, maximizing the absorptive capacity of the remnant
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bowel, and reducing or eliminating the need for PS.5,14
Whereas traditional treatment modalities for SBS have
focused on reducing malabsorptive losses through dietary
modification and antidiarrheal/antisecretory agents,5,15 there
has been interest in novel therapeutic approaches that
enhance the absorptive capacity of the remnant bowel and
decrease the need for PS.16,17 Teduglutide is a stable
recombinant analog of glucagon-like peptide 2, a trophic
hormone secreted by intestinal L cells.18–20 Teduglutide is
approved in the United States and Europe for use in adult
patients with SBS who are dependent on PS. In phase III
studies, teduglutide enhanced intestinal absorption and
reduced PS requirements in patients with SBS-IF.17,21 In the
pivotal 24-week, multicenter, multinational, double-blind,
placebo-controlled trial, 63% (27/43) of patients receiving
teduglutide 0.05 mg/kg/day achieved the primary end point
(20–100% reduction from baseline in weekly PS volume at
weeks 20 and 24) compared with 30% (13/43) of patients
receiving placebo (P=0.002). Mean PS volume reductions
were 4.4 and 2.3 l/week among the treatment and placebo
groups, respectively (P≤0.001). The most common adverse
events (AEs) reported in teduglutide-treated patients were
gastrointestinal related, including abdominal pain, nausea,
stoma complications, and abdominal distension.17
The current study (STEPS-2) was a 24-month, open-label
extension of the initial placebo-controlled study undertaken to
assess the long-term safety, tolerability, and clinical efficacy of
teduglutide in patients with SBS-IF.
METHODS
Study design and patients. STEPS-2 was a 2-year, open-
label extension study that included patients from 25 centers
in nine European and North American countries (Clinical-
Trials.gov identifier: NCT00930644). The study protocol was
reviewed and approved by the institutional review boards/
independent ethics committees/research ethics boards. All
patients who met the inclusion/exclusion criteria17 and
completed 24 weeks of treatment in the initial placebo-
controlled study with either teduglutide or placebo were
eligible to enroll (Figure 1). In addition, patients who
completed the fluid optimization and stabilization phases of
the initial placebo-controlled study17 to establish baseline PS
requirements but were not randomized because of full study
enrollment could enroll directly into STEPS-2. All patients
received a daily subcutaneous injection of 0.05 mg/kg/day
teduglutide for up to 24 months. The study population
included three patient subgroups: those who received
teduglutide in the initial placebo-controlled study and
STEPS-2 (TED/TED), those who received placebo in the
initial placebo-controlled study followed by teduglutide in
STEPS-2 (PBO/TED), and those who received no treatment
in the initial placebo-controlled study followed by teduglutide
in STEPS-2 (NT/TED). Including study drug exposure during
the placebo-controlled trial, total exposure to teduglutide at
the end of STEPS-2 was up to 30 months for TED/TED and
up to 24 months for the NT/TED and PBO/TED subgroups.
Protocol for PS adjustments. All patients enrolled in
STEPS-2, including the NT/TED subgroup not randomized to
treatment in the initial placebo-controlled study, had undergone
a period of strict PS optimization and stabilization at the start of
the initial placebo-controlled study to establish stable, minimal
weekly PS volumes while maintaining appropriate hydration
(i.e., urine outputs between 1 and 2 l/day).17 During the
extension study, PS volume adjustments of 10–30% were
made according to the placebo-controlled study algorithm17
but at less frequent intervals. Details are provided in
the Supplementary Materials online (study results are also
posted to the ClinicalTrials.gov website (study identifier:
NCT00930644)).
Safety and efficacy measures. Clinical evaluations were
performed as outlined in the Supplementary Materials.
Colonoscopies were performed at the start of the initial
placebo-controlled study and at the end of STEPS-2 in those
patients with colons for the purpose of polyp surveillance.
Completed Initial 24-Week, 
Placebo-Controlled Study 
Up to 2 years 
PBO/TED 
Teduglutide 0.05 mg/kg/day 
Placebo 
n=39 
TED/TED 
Teduglutide 0.05 mg/kg/day 
Teduglutide 0.05 mg/kg/day 
n=37 
Baseline
NT/TED 
Teduglutide 0.05 mg/kg/day 
Not Treated in 24-Week Study* 
n=12 
Baseline
Baseline
Direct Enrollment
Figure 1 STEPS-2 study design. All patients who completed 24 weeks of treatment in the initial placebo-controlled study with either teduglutide or placebo or who completed
the fluid optimization and stabilization phases in the initial placebo-controlled study but were not randomized were eligible for enrollment. Baseline was considered to be the start
of teduglutide treatment. *Patients who completed fluid optimization and stabilization but were not randomized in the initial 24-week placebo-controlled study because of full study
enrollment were eligible for direct enrollment into STEPS-2. NT/TED, received no treatment in the initial placebo-controlled study and teduglutide in STEPS-2; PBO/TED, received
placebo in the initial placebo-controlled study and teduglutide in STEPS-2; TED/TED, received teduglutide in the initial placebo-controlled study and in STEPS-2.
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Patients were evaluated for antibodies to teduglutide and
plasma citrulline levels, as described in the Supplementary
Materials.
Efficacy end points included the change in PS volume from
baseline, the percentage of patients achieving a response
(≥20% reduction in PS volume from baseline), duration of
response, reduction in days of PS per week, and the number of
patients who achieved independence from PS.
Data analysis. The primary patient population for all
analyses was the intent-to-treat population, defined as all
patients who signed informed consent. The safety population
included all patients who received at least one dose of study
drug. For safety analyses, patients with no previous exposure
to teduglutide (PBO/TED and NT/TED subgroups) were
combined. For efficacy analyses, data for each subgroup
were considered separately because patients in the NT/TED
subgroup were not randomized in the initial 24-week placebo-
controlled study and therefore did not participate in that
study’s regimented, regularly scheduled study visits, includ-
ing the protocol-driven efforts at PS reduction.
Treatment-emergent AEs (TEAEs) were coded using the
Medical Dictionary for Regulatory Activities and summarized
using descriptive statistics. TEAEs were categorized as
related to treatment if a causal relationship to the study drug
could not be ruled out. Onset of TEAEs was based on the
study period of STEPS-2, regardless of treatment in the initial
placebo-controlled study. Missing safety parameters were not
imputed.
Descriptive statistics summarized the change from baseline
in efficacy variables at each time point. The study was not
sufficiently powered to determine the statistical significance of
safety or efficacy end points. Baseline was determined by the
initial exposure to teduglutide. Therefore, baseline was
considered the last visit before teduglutide treatment in the
initial placebo-controlled study for TED/TED and the last visit
before teduglutide treatment in STEPS-2 for PBO/TED and
NT/TED.17Weekly PS volumewas calculated from the 2-week
interval before a visit based on patient diary entries. Missing
PS volumes from patient diaries were not imputed, and a
maximum of five missing days from each 2-week interval was
allowed; otherwise, the interval was classified as missing.
RESULTS
Patients. Of the 78 patients who completed the initial
placebo-controlled study and were eligible for STEPS-2, 76
enrolled in the extension (n=37 TED/TED; n=39 PBO/TED).
An additional 12 patients who were screened and optimized in
the placebo-controlled study but not randomized were enrolled
directly in STEPS-2. Of the 88 patients enrolled in STEPS-2,
65 (74%) completed the study (n=30/37 TED/TED; n=29/39
PBO/TED; n=6/12 NT/TED). In the TED/TED subgroup,
seven patients discontinued because of AEs (n=4; three were
TEAEs, described below, and one was an ongoing event (non-
treatment-emergent AE) that originated during the initial
placebo-controlled study), patient decision (n=2), and death
(n=1; case of catheter-related sepsis described below). In the
combined NT/TED and PBO/TED subgroups, 16 patients
discontinued because of AEs (n=12), patient decision (n=2),
or investigator decision (n=2). Patient characteristics and
demographics (Table 1) were similar among the three
subgroups.
All 88 patients who signed the consent form received at least
one dose of teduglutide; therefore, the safety and intent-to-treat
populationswere identical. Of the 88 patients, 81 (92%) received
≥80% of planned doses: 32/37 (87%) in TED/TED and 49/51
(96%) in the combined NT/TED and PBO/TED subgroups.
Safety and tolerability. TEAEs were reported in 84/88
(95%) patients; 46 patients (52%) had TEAEs that were
considered treatment related. Most patients experienced
TEAEs that were mild or moderate in severity. The most
common TEAEs are listed in Table 2.
Treatment-emergent serious AEs (TESAEs) occurred in
56/88 (64%) patients (Table 3): 24 (65%) in TED/TED and
Table 1 Baseline demographics and characteristics of the overall study population
Characteristic TED/TED (n=37) PBO/TED (n= 39) NT/TED (n=12) All Patients (N=88)
Mean (s.d.) age, years 51.8 (12.5) 50.4 (15.9) 50.0 (13.9) 50.9 (14.2)
Mean (s.d.) body weight, kg 62.7 (12.1) 61.1 (13.2) 65.8 (12.9) 62.4 (12.6)
Mean (s.d.) BMI, kg/m2 22.3 (3.3) 22.0 (3.2) 22.9 (3.9) 22.3 (3.3)
Men, n (%) 18 (49) 17 (44) 6 (50) 41 (47)
Reason for resection, n (%)
Vascular disease 12 (32) 15 (38) 2 (17) 29 (33)
Crohn’s disease 8 (22) 7 (18) 1 (8) 16 (18)
Volvulus 3 (8) 6 (15) 2 (17) 11 (13)
Injury 4 (11) 3 (8) 0 7 (8)
Cancer 1 (3) 2 (5) 0 3 (3)
Other 9 (24) 6 (15) 7 (58) 22 (25)
Colon-in-continuity, n (%) 24 (65) 23 (59) 7 (58) 54 (61)
Mean (s.d.) percentage of colon remaining 55 (21) 70 (27) 60 (37) 63 (27)
Median (range) estimated remaining small intestine,a cm 60.0 (20–250) 43.0 (5–170) 45.0 (15–150) 50.0 (5–250)
Stoma, n (%) 17 (46) 14 (36) 5 (42) 36 (41)
Mean (range) time since start of PS dependence, years 7.0 (1.0–24.7) 6.0 (1.0–25.8) 6.2 (1.1–20.8) 6.4 (1.0–25.8)
BMI, body mass index; NT/TED, received no treatment in the initial placebo-controlled study and teduglutide in STEPS-2; PBO/TED, received placebo in the initial
placebo-controlled study and teduglutide in STEPS-2; PS, parenteral support (parenteral nutrition and/or intravenous fluids); TED/TED, received teduglutide in the
initial placebo-controlled study and in STEPS-2.
aIncludes only patients with known residual small intestine length.
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32 (63%) in the combined NT/TED and PBO/TED subgroups.
Nine of 88 (10%) patients experienced TESAEs considered by
the clinical site investigator to be related to teduglutide
treatment. These were gastrointestinal stoma complications
and abdominal pain (n= 2 for each), and exacerbation of
Crohn’s disease, intestinal obstruction, injection site hema-
toma, cholecystitis, portal hypertension, blood bilirubin
increased, metastatic neoplasm (case history for patient with
metastatic adenocarcinoma described below), and hyperten-
sion (n= 1 for each).Weight losswas not reported as a serious
AE (SAE) in any patient.
Three deaths occurred during the study. A 70-year-old man
in the TED/TED subgroup with SBS as a result of major
intestinal resection secondary to mesenteric artery embolism
was hospitalized with catheter-related sepsis and urinary tract
infection following 28 months of teduglutide. The patient died
15 days after hospitalization, despite empiric antibiotic
treatment. Sepsis in this patient was considered unrelated to
teduglutide, and no change was made to his teduglutide
treatment regimen during these events. A 48-year-old man in
the NT/TED subgroup was diagnosed with metastatic adeno-
carcinoma to the liver of unconfirmed origin 11 months after
starting teduglutide treatment. This patient had a history of
Hodgkin’s disease treated with chemotherapy and abdominal
radiation two decades before receiving teduglutide. The
investigator considered the patient’s prior Hodgkin’s disease
and treatment course of chemotherapy and radiotherapy to be
risk factors for neoplasm; however, the event was reported as
treatment related. Six months before starting teduglutide
therapy, the patient had undergone a computed tomography
(CT) of the abdomen, which showed liver enlargement.
A subsequent review of this CT and a second CT scan
performed after initial back pain symptom onset (almost
11months after teduglutide initiation) revealed a focal lesion in
the liver that had not been reported on the initial CT.
Teduglutide was discontinued (13 days before death) and
a biopsy of the liver lesion (8 days before death) revealed
metastatic adenocarcinoma with primary tumor likely to be
located in the gastrointestinal tract (precise location unknown).
A 64-year-old man in the PBO/TED subgroup was diagnosed
with non-small-cell lung cancer 3 months after starting
teduglutide. This patient had an extensive smoking history
(about 30 cigarettes per day for about 30 years). In addition,
during his career as a technician, the patient had been exposed
to asbestos for an unknown period of time. Teduglutide was
discontinued upon diagnosis (5 months before death), and the
event was considered unrelated to the study drug. A third
patient was diagnosed with cancer during STEPS-2. A 74-year-
oldman in the TED/TED subgroupwith a history of smoking (10
cigarettes per day for 5 years and stopped approximately 25
years ago) was diagnosed with lung squamous cell carcinoma
more than 1 year after starting teduglutide and withdrew from
the study. The event was not considered related to teduglutide
and was ongoing as of last follow-up.
Fifty patients underwent 51 colonoscopies during or as
follow-up for the STEPS-2 study. Gastrointestinal polyps were
reported in nine patients (n=3 TED/TED; n= 6 PBO/TED)
within or at the end of the 24-month treatment period with
teduglutide. Of these nine patients, two had polyps at
baseline. Histopathology classifications were adenoma
(n= 5), hyperplastic polyp (n= 1), and rectal inflammatory
polyp (n= 1) and unclassified (n= 2; colonoscopieswere done
outside of the study procedures). There were no cases of
intestinal dysplasia or malignancy.
Teduglutide-specific antibodies were detected in 37/87
patients (43%; n=18/37 (49%) TED/TED and n=19/50
(38%) combined NT/TED and PBO/TED) during STEPS-2.
No neutralizing antibodies to teduglutide were detected.
Clinical parameters, including weekly PS volume, duration of
Table 2 Treatment-emergent adverse events occurring in ≥10% of study
patients
Adverse event, n (%) All patients, N= 88
Abdominal pain 30 (34)
Catheter sepsis 25 (28)
Episodes of weight decrease 22 (25)
Asthenic conditions 20 (23)
Febrile disorders 18 (20)
Nausea 17 (19)
Urinary tract infections 16 (18)
Catheter site-related reactions 15 (17)
Upper respiratory tract infections 15 (17)
Abdominal distension 14 (16)
Diarrhea 13 (15)
Musculoskeletal pain 13 (15)
Gastrointestinal stomaa complications 12 (33)
Dehydration 12 (14)
Fluid overload 12 (14)
Headaches 10 (11)
Hypersensitivity 9 (10)
Muscle spasms 9 (10)
Flatulence 9 (10)
Vomiting 9 (10)
aOnly among patients with stoma (n= 36).
Table 3 Treatment-emergent serious adverse events by system organ class
and preferred term occurring in ≥ 2 patients
System organ class preferred term, n (%) All patients N=88a
Infections and infestations 34 (39)
Central line infection 8 (9)
Catheter bacteremia 4 (5)
Catheter sepsis 4 (5)
Sepsis 4 (5)
Catheter-related infection 3 (3)
Pneumonia 3 (3)
Urinary tract infection 3 (3)
Catheter site infection 2 (2)
Gastroenteritis 2 (2)
Gastrointestinal disorders 9 (10)
Crohn’s disease 2 (2)
General disorders and administration site
conditions
8 (9)
Pyrexia 5 (6)
Injury, poisoning, and procedural
complications
8 (9)
Gastrointestinal stoma complicationb 2 (6)
Vascular disorders 6 (7)
Subclavian vein thrombosis 2 (2)
Investigations 2 (2)
Blood bilirubin increased 2 (2)
aIntent-to-treat population.
bOnly among patients with stoma (n= 36).
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response, plasma citrulline levels, or occurrence of AEs
related to immunogenicity, were similar between antibody-
positive and antibody-negative patients.
Vital signs were stable during the study. Despite decreases
in PS volume throughout the study, mean body weight and
body mass index remained constant (mean± s.d. at end of
treatment: −0.4±5.0 kg and − 0.2±1.7 kg/m2, respectively).
No substantial shifts occurred in plasma calcium, magnesium,
or phosphate (Supplementary Table S1). Mean albumin levels
remained stable; mean liver enzyme levels either numerically
decreased or remained near baseline (Supplementary Table
S2). In the subset of patients who showed ≥50% reduction
from baseline in their PS volume requirements at month 24,
all mean liver enzymes numerically declined by month 1 and
month 24. There were no changes from baseline in kidney
function tests, including plasma creatinine levels.
Efficacy. PS volume reductions were observed across all
subgroups (Table 4), with the greatest reductions seen in the
subgroup with the longest duration of exposure to teduglu-
tide, TED/TED. In the intent-to-treat population (N=88),
89% of the TED/TED (n=33/37), 46% of the PBO/TED
(n= 18/39), and 50% of the NT/TED (n= 6/12) subgroups
achieved a clinical response, defined as a ≥ 20% reduction in
PS volume from baseline at the last visit. Mean reductions in
PS volume from baseline to the last dosing visit in the intent-
to-treat population were 6.8 l/week (−59%) for TED/TED
(n= 36), 2.9 l/week (−25%) for PBO/TED (n=36), and
3.3 l/week (−19%) for NT/TED (n=10).
Among those who completed STEPS-2, 28/30 (93%) TED/
TED patients, 16/29 (55%) PBO/TED patients, and 4/6 (67%)
NT/TED patients achieved a clinical response (Table 4).
Response to teduglutide was maintained over long-term
treatment. In the TED/TED subgroup, 21/22 patients (95%)
who achieved a clinical response with teduglutide during the
initial placebo-controlled study maintained a ≥ 20% PS
volume reduction after a further 24 months of continuous
treatment in STEPS-2. PS volume requirements decreased
progressively over the course of up to 30 months of treatment
(Figure 2a). These mean reductions in prescribed PS volume
translated into at least one additional day per week free from
infusion for 38/65 patients who completed 24 months of
treatment (Figure 2b).
In addition, 13 patients obtained enteral autonomy and
independence from PS during STEPS-2 (n= 10 TED/TED;
n=2 PBO/TED; n= 1 NT/TED; Figure 2b). Demographic and
disease characteristics varied widely among these patients:
baseline PS volume ranged from 3.5 to 13.4 l/week; nine
patients had colon-in-continuity; and five patients had a stoma
(three with jejunostomy and two with colonostomy). Indepen-
dence from PS occurred after teduglutide treatment ranging
from 28 to 127 weeks and after up to 15.5 years of PS
dependence. The patient who obtained enteral autonomy after
15.5 years of PS dependence was a 63-year-old man with
SBS as a result of mesenteric thrombosis who had colon-in-
continuity and 26 cm of small bowel remaining. He had a
baseline PS requirement of 13.4 l/week and had been
receiving teduglutide for 115 weeks as of his first visit off of PS.
The onset to clinical response in PS volume reductions was
delayed in some patients. Of eight patients in the TED/TED
group who were nonresponders in the placebo-controlled
study and completed STEPS-2, seven (88%) achieved a
clinical response in STEPS-2. At baseline, these seven “slow
responders” had a mean weekly PS volume requirement of
12.7 (range, 3.5–26.6) l/week, and had been dependent on PS
for 1.1–9.8 years. In addition, all seven slow responders had
colon-in-continuity; remnant small bowel lengths ranged from
30 to 120 cm. Causes of SBS in these patients were vascular
disease (n= 4), strangulated small intestine (n=1), injury
(n=1), and Crohn’s disease (n=1). The slow responders
achieved PS volume reductions of 3.1–16.6 l/week (percen-
tage reduction of 29–100%) over 24–104 weeks of treatment
with teduglutide. Three of these seven patients achieved
complete independence from PS. The single nonresponding
patient, who failed to obtain the protocol-defined clinical
response with teduglutide in either initial placebo-controlled
study or STEPS-2, experienced a 17% reduction from
baseline in weekly PS volume during the extension study.
Mean plasma citrulline levels increased numerically in all
study subgroups. Mean baseline values were 18.4 μM for
Table 4 Parenteral support volume reductions
All patientsa (N=88) Completers (n= 65)
TED/TED
(n=37)
PBO/TED
(n=39)
NT/TED
(n=12)
TED/TED
(n= 30)
PBO/TED
(n=29)
NT/TED
(n=6)
Baseline PS requirement, l/weekb 12.3 11.4 14.2 12.4 10.4 12.8
Clinical response,c n (%)d 33 (89) 18 (46) 6 (50) 28 (93) 16 (55) 4 (67)
Mean PS reduction from baseline, l/week (s.d.) 6.8 (4.9) 2.9 (3.9) 3.3 (3.7) 7.6 (4.9) 3.1 (3.9) 4.0 (2.9)
Percentage reductione 59 25 19 66 28 39
ITT, intent-to-treat; NT/TED, received no treatment in the initial placebo-controlled study and teduglutide in STEPS-2; PBO/TED, received placebo in the initial placebo-
controlled study and teduglutide in STEPS-2; PS, parenteral support (parenteral nutrition and/or intravenous fluids); TED/TED, received teduglutide in the initial
placebo-controlled study and in STEPS-2.
aLast dosing visit in the ITT population.
bLast dosing visit population is n= 36, n= 36, n= 10, respectively. Baseline determined by start of teduglutide treatment: at randomization in the initial placebo-
controlled study for TED/TED patients (30 months of teduglutide treatment) and at start of STEPS-2 for PBO/TED and NT/TED patients (24 months of teduglutide
treatment).
c20–100% PS volume reduction from baseline.
dLast dosing visit ITT population is n= 37, n= 39, n= 12, respectively.
eLast dosing visit ITT population is n= 36, n= 36, n= 10, respectively.
Long-Term Teduglutide Treatment for SBS-IF
Schwartz et al.
5
Clinical and Translational Gastroenterology
TED/TED, 16.7 μM for PBO/TED, and 17.3 μM for NT/TED
subgroups. At month 24, mean± s.d. plasma citrulline rose
to 32.7±23.1 μM (+71%) in the TED/TED subgroup, to
25.9±25.4 μM (+42%) in the PBO/TED subgroup, and to
19.5±9.1 μm (+29%) in the NT/TED subgroup.
DISCUSSION
Data from the open-label, 24-month STEPS-2 study support
the overall safety conclusion that long-term treatment with
teduglutide is well tolerated and that efficacy is maintained or
enhanced. Most patients completed the study, suggesting that
teduglutide was generally well tolerated. Many of the observed
AEs were consistent with the known mechanism of action
of teduglutide or the underlying condition of SBS or were
complications associated with PS. As in the placebo-
controlled studies, gastrointestinal-related AEs were frequent,
with abdominal pain being the most commonly reported
AE during the study.17,21 This was as anticipated because
gastrointestinal symptoms are a typical manifestation of SBS
itself.22 In addition, long-term use of narcotic agents, which are
often prescribed to decrease intestinal motility in SBS, is
associated with gastrointestinal complaints, including abdom-
inal pain, constipation, bloating, nausea, and vomiting.15,23
Catheter sepsis was also a common AE, and catheter-related
complications were among the most common SAEs. Although
catheter-related SAEs in this study were not considered to be
related to teduglutide, these events underscore the prevalence
of catheter-related complications and the importance of
meticulous catheter care for patients who require chronic PS.
Three cases of cancer were reported during the study. Two
patients with significant smoking histories were diagnosed
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with lung cancer, and one patient with a history of Hodgkin’s
disease treated with chemotherapy and radiotherapy devel-
oped metastatic adenocarcinoma. Each of these patients
had a significant risk factor for malignancy. The causal
link between smoking and lung cancer has been well
established.24 Similarly, survivors of Hodgkin’s disease are
at increased risk of secondary cancers, which are the leading
cause of death in this population.25,26 However, because a
causal relationship with teduglutide treatment and the case of
metastatic adenocarcinoma could not be ruled out, that event
was reported as treatment related. Neither of the other two
cancer cases was considered related to teduglutide. None-
theless, because teduglutide is an intestinotrophic hormone,
treated patients should be monitored for signs of intestinal
neoplasia, and use of teduglutide should be discontinued if
neoplasm is detected. Furthermore, continued clinical assess-
ment of risk of teduglutide with regard to neoplastic growth is
warranted.
Gastrointestinal polyps were reported in 9 of 51 (18%)
patients who received colonoscopies. This prevalence rate is
in line with recommended target adenoma detection rate for
first-time colonoscopies (≥15% and ≥25% for women aged
≥50 years andmen aged450 years, respectively).27 Further-
more, none of the seven biopsied polyps were malignant.
Although the ideal schedule for colonoscopy surveillance of
teduglutide-treated patients has yet to be determined, these
findings support the recommendation to monitor patients
receiving teduglutide with regular colonoscopies.28
The nutrition and hydration status of teduglutide-treated
patients was conserved in this study, despite PS volume
reductions. Some patients experienced episodes of
decreased weight during the study, which were reported as
AEs. However, mean weight among the study group as a
whole remained constant, suggesting that weight loss in
individual patients was transient. Furthermore, mean body
mass index did not change over the course of the study, which
may indicate that weight fluctuations resulted from fluid
effects. Mean kidney function tests and electrolyte levels were
also stable. Mean albumin levels remained steady between
baseline and end of treatment. This observation suggests that
hydration and nutrition status was generally stable,29 even
though patients were challenged with reduction or elimination
of PS.Mean liver enzyme values either numerically decreased
or remained constant during this study. The most dramatic
decreases were observed among the subset of patients with
≥50% reduction in PS volume requirements; this is a notable
finding, considering that liver disease is a life-threatening
complication of chronic PS.30
In this study, long-term teduglutide treatment for up to 2 years,
or up to 30 months for a subset of the study population, was
associated with continued efficacy as reflected by continued
reductions in PS volume, a gain in number of days off PS per
week, and achieving complete independence from PS. One of
the greatest values associated with teduglutide is the potential
to eliminate the need for PS in some patients. Complete enteral
autonomy eradicates the risks associated with catheter
dependence and chronic PS infusion.7 However, PS reductions
that permit partial weaning and gaining additional days off PS
are also powerful, with the potential to increase quality of life
and reduce PS-associated complications. Indeed, among
patients with SBS-IF, decreases in PS requirements are
associated with significantly higher scores on an SBS-specific
quality-of-life instrument.31
The results of this long-term study demonstrate the
durability of the effects of teduglutide. Almost all patients
(21/22) in the TED/TED subgroup who achieved a clinical
response (≥20% reduction from baseline in weekly PS volume
at Weeks 20 and 24) with teduglutide in the initial placebo-
controlled study maintained their response after an additional
24 months of treatment. In addition, a progressive increase in
clinical benefit was observed with long-term teduglutide
treatment. Mean PS volume requirements declined steadily
over 30 months of treatment among patients who received
teduglutide in both the initial 24-week placebo-controlled study
and the STEPS-2 extension study. Furthermore, the percen-
tage of patients achieving additional days off PS increased
with longer treatment time; among teduglutide-treated patients
who completed 30 months of treatment in the initial placebo-
controlled study and STEPS-2, 60% (18/30) achieved
a ≥2-day reduction in PS infusions per week compared with
21% (8/39) of patients who received teduglutide for 24 weeks
in the initial placebo-controlled study.17
Responses to teduglutide were observed in all 3 subgroups.
The greatest improvements with teduglutide were observed in
the TED/TED subgroup, which received the longest duration
of therapy (up to 30 months). Nevertheless, PBO/TED and
NT/TED patients, who initiated teduglutide during STEPS-2
for a total of up to 24months of treatment, also incurred clinical
benefits (e.g., response rates of 55 and 67% and mean PS
volume decreases of 3.1 and 4.0 l/week, respectively, for study
completers). Protocol differences between the 2 studies may
account for some of the variation in response among treatment
subgroups. The initial placebo-controlled study, which was
designed to assess the efficacy of teduglutide relative to
placebo, implemented a stricter protocol for PS weaning than
did the extension study, which was designed to provide long-
term, open-label safety and efficacy data, with less frequent
study visits (on average, every 3 months). Although they did
not receive teduglutide treatment in the initial placebo-
controlled study, patients in the PBO/TED subgroup benefited
from themore aggressive weaning algorithm. As a result of this
intensive management, patients in the placebo group in the
initial placebo-controlled study achieved a 2.3-l/week (21%)
reduction in PS volume requirements at the end of that study.17
These patients, who had lower baseline PS requirements at
the start of STEPS-2, achieved an additional 3.1-l/week (28%)
reduction in PS volume requirements with 24 months of
teduglutide during the extension study. Between Months 3 and
24 of STEPS-2, patients were evaluated for PS reductions less
frequently than during the initial placebo-controlled study; this
may partially explain why the response to teduglutide treatment
in the NT/TED group at Month 24 was somewhat weaker
than the response in the teduglutide arm in the initial
placebo-controlled study at Month 6 (−4.0 vs. −4.4 l/week,
respectively).17 However, the small size of the subgroups,
particularly the NT/TED subgroup (n=12), limits the ability
to draw firm conclusions from subgroup comparisons.
Although some patients showed an early response to
teduglutide, others had a delayed response. Seven of
8 patients who did not achieve the response criteria of
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≥20% reduction in PS in the initial placebo-controlled study
showed dramatic reductions in PS with longer exposure to
teduglutide in STEPS-2 (29–100% reduction in weekly PS
volume after 24–104 weeks of treatment). Three of these slow
responders eventually achieved enteral autonomy. The
mechanisms underlying this delayed response are currently
unclear. Baseline PS volume requirements were similar
between the slow responders and the study population as
a whole (mean of 12.7 l/week for the slow responders vs.
11.4–14.2 l/week for the 3 STEPS-2 subgroups). However, the
slow responders were somewhat earlier in their postresection
clinical course than the full study group (range for duration
of PS dependency at baseline of 1.1–9.8 vs. 1.0–25.8 years,
respectively). Therefore, the slow responders may have
required additional time to achieve their full endogenous
adaptive potential, which was then augmented by teduglutide
treatment.4 Nonetheless, this finding suggests that there is no
specified time at which to consider discontinuation of teduglu-
tide for lack of efficacy. Rather, the physician should consider
the patient’s entire clinical picture, including hydration status,
oral intake, fecal/stomal output, and time after resection when
deciding whether to continue teduglutide therapy.
Efficacy and safety should be closely monitored on an
ongoing basis in all patients, and clinical decisions should be
guided by treatment objectives, physician judgment, and
patient preferences.32 The decision of how long to continue
teduglutide also should be considered in the context of recent
data from a large series of adult patients with SBS (N=268)
followed up for up to 24 years. Amiot et al. found that intestinal
adaptation can continue for considerably longer than once
thought (i.e., up to 5 years following resection); the analysis
also confirmed that 10-year survival is considerably worse
among patients with SBS who remain dependent on PS
(40.7%±0.5%) compared with those who become indepen-
dent of PS (67.0%± 0.6%, Po0.001).33
The limitations of this study are primarily those shared by
open-label observational studies. Furthermore, the study
population is necessarily small, given the rarity of the
condition, and heterogeneous with 3 patient subgroups who
received treatment for different durations. Patient response to
teduglutide appeared to vary, and thus, it is unclear how each
phase of study attributed to the observed benefits of teduglu-
tide. Because this extension study was not placebo-controlled,
we cannot rule out the possibility that observed reductions in
PS were partially caused by spontaneous adaptation, which
has previously been documented in adultswith intestinal failure
after more than 5 years of PS dependence.33,34
In STEPS-2, the longest and largest study yet conducted
in patients with SBS-IF, long-term treatment with teduglutide
resulted in sustained and continued reductions in PS
requirements while overall health and nutritional status
was maintained. PS volume reductions were observed
in the majority of patients who completed the study, and
13 patients (20% of study completers) with varying baseline
characteristics achieved enteral autonomy and independence
from PS. Together, these data provide further evidence of the
ability of teduglutide to enhance intestinal absorptive capacity.
The most common AEs associated with teduglutide in this
long-term study were consistent with the placebo-controlled
trials and with the disease state of SBS-IF.17,21 Nonetheless,
further long-term data on safety and sustained durability of
effect of teduglutide in patients with SBS-IF are warranted;
the ongoing global registry study (ClinicalTrials.gov identifier:
NCT01990040) will add to the accruing body of knowledge.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Teduglutide, a glucagon-like peptide 2 analog, is an
intestinotrophic agent that promotes intestinal adaptation.
✓ In short-term, placebo-controlled trials, teduglutide reduced
PS requirements in patients with SBS-IF.
WHAT IS NEW HERE
✓ Long-term teduglutide treatment is associated with
sustained responses and accrued benefit.
✓ Teduglutide-treated patients experienced continued
reductions in PS over long-term treatment; some achieved
PS independence.
✓ Overall health and nutritional status were maintained
despite PS reductions.
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